New cancer drug BBI-355 trial halted early – what we know
NCT ID NCT05827614
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a new oral drug called BBI-355, alone or with other targeted therapies, in people with advanced solid tumors that had extra DNA (oncogene amplifications). The study aimed to find the safest dose and check for side effects. It was terminated early, so full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BBI-355 (a CHK1 inhibitor drug)
What this could lead to
If successful, this could point toward a new treatment option for certain advanced cancers that have extra DNA in their cells.
What could go wrong
This was a very early (Phase 1/2) study that was terminated, so results are limited. The drug may not prove safe or effective, and it was tested only in people who had already tried all standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK (HNSCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Florida Cancer Specialists
Lake Mary, Florida, 32746, United States
-
HealthONE
Denver, Colorado, 80218, United States
-
MD Anderson Cancer Center
Houston, Texas, 77054, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
NEXT Oncology
Fairfax, Virginia, 22031, United States
-
NEXT Oncology - Dallas
Irving, Texas, 75039, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
Sarcoma Oncology
Santa Monica, California, 90403, United States
-
The University of Kansas
Fairway, Kansas, 66205, United States
-
UCLA Medical Center
Los Angeles, California, 90095, United States
-
University of Washington, Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
University of Wisconsin
Madison, Wisconsin, 53792, United States